Lymphocyte antigen 75 （Ly75）, also known as CD205, CLEC13B, GP200-MR6, and DEC-205, is a type I transmembrane protein predominantly expressed on dendritic cells and thymic epithelial cells. Ly75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has demonstrated strong preclinical anti-tumor activity in lymphoma models.
Upon verification as a monotherapy in vivo, the antibody-drug conjugate （ADC） has been found to have a synergistic effect when combined with the BCL2 inhibitor Venetoclax and the anti-CD20 monoclonal antibody rituximab.